Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma
NCT ID: NCT04987944
Last Updated: 2024-07-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
45 participants
INTERVENTIONAL
2021-10-18
2023-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AMG 761 in Adults With Asthma
NCT01514981
A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen
NCT04187508
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
NCT01197794
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma
NCT02219048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BHV3500
Zavegepant 150 mg BID
Zavegepant
150 mg BID
Placebo
Matching placebo 150 mg BID
Placebo
Placebo matching active drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zavegepant
150 mg BID
Placebo
Placebo matching active drug
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
University of Calgary
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
The Lung Centre- Vancouver General Hospital
Vancouver, British Columbia, Canada
The Lung Centre-Vancouver General Hospital
Vancouver, British Columbia, Canada
McMaster University
Hamilton, Ontario, Canada
McMaster Universtiy
Hamilton, Ontario, Canada
Institut universitaire en cardiologie et pneumologie de Quebec-Universite Laval-(IUCPQ-UL)
Québec, Quebec, Canada
University of Saskatchewan/Royal University Hospital
Saskatoon, Saskatchewan, Canada
Institut universitaire en cardiologie et pneumologie de Quebec-Universite Laval-(IUCPQ-UL)
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C5301005
Identifier Type: OTHER
Identifier Source: secondary_id
BHV3500-204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.